Business Context and Reporting Period
This Form 8-K Current Report was filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on December 23, 2014. The registrant is incorporated in Delaware and maintains its principal executive offices in Cambridge, Massachusetts. The report addresses a specific corporate governance event occurring on the date of the report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the resignation of Stephen Kraus from the Board of Directors. He also stepped down from the Compensation Committee and the Nominating and Corporate Governance Committee. The company explicitly stated that his resignation was not the result of a disagreement on any matter related to the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the specific event of the director's departure.
Key Facts for Investor Verification
- Stephen Kraus resigned from the OvaScience, Inc. Board of Directors and all committee assignments on December 23, 2014.
- The resignation was voluntary and not due to any disagreement with the company.
- The report was signed by Jeffrey E. Young, Chief Financial Officer, on December 24, 2014.
- No financial data or operational metrics are included in this specific filing.